|AHFS/Drugs.com||International Drug Names|
|By mouth (tablets)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||315.413 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.
Mitiglinide is delivered in tablet form.
- "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names (Rec. INN): List 40" (PDF). World Health Organization. p. 187. Retrieved 10 November 2016.
- Malaisse WJ (October 2008). "Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients". Expert Opinion on Pharmacotherapy. 9 (15): 2691–8. doi:10.1517/14656522.214.171.12491. PMID 18803455.
- Elixir Pharmaceuticals — website of the U.S. rights holder for mitiglinide.